exs21546
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 8, 2020 (NCT04727138)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Alpha-2a adrenergic receptorANTAGONIST
ADRA2A antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05920408 | Phase 1/Phase 2 (Phase 2) | Apr 11, 2023 | Biotrial, Exscientia Limited |
| NCT04727138 | Phase 1 | Dec 8, 2020 | Exscientia Limited, Quotient |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Exscientia Limited | For profit | 2 | 2 | 2 | 2020 |
| Biotrial | For profit | 1 | 0 | 1 | 2023 |
| Quotient | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1